Blinatumomab in relapsed/refractory diffuse large B cell lymphoma

Ann Hematol. 2017 Oct;96(10):1759-1762. doi: 10.1007/s00277-017-3088-5. Epub 2017 Aug 5.

Authors

Ruben Van Dijck¹, Ann Janssens², Daan Dierickx², Michel Delforge², Olivier Gheysens³, Thomas Tousseyn⁴, Gregor Verhoef⁵

Affiliations

¹ Department of Internal Medicine, Leuven University Hospitals, Leuven, Belgium.
² Department of Hematology, Leuven University Hospitals, Herestraat 49, 3000, Leuven, Belgium.
³ Department of Nuclear Medicine, Leuven University Hospitals, Leuven, Belgium.
⁴ Department of Pathology, Leuven University Hospitals, Leuven, Belgium.
⁵ Department of Hematology, Leuven University Hospitals, Herestraat 49, 3000, Leuven, Belgium. gregor.verhoef@uzleuven.be.

PMID: 28779352
DOI: 10.1007/s00277-017-3088-5

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Antibodies, Bispecific / therapeutic use*
Chemotherapy, Adjuvant
Drug Resistance, Neoplasm* / drug effects
Hematopoietic Stem Cell Transplantation
Humans
Lymphoma, Large B-Cell, Diffuse / drug therapy*
Lymphoma, Large B-Cell, Diffuse / pathology
Lymphoma, Large B-Cell, Diffuse / therapy
Male
Recurrence
Transplantation, Homologous
Treatment Failure

Substances

Antibodies, Bispecific
blinatumomab